WEE1 and small cell lung carcinoma: Preclinically, WEE1 inhibition has demonstrated an antitumor effect via cell cycle arrest and apoptosis in SCLC and other neuroendocrine-associated malignancies [176–178], thereby emerging as a therapeutic target for NECs.